Study Published in the Journal Infection Demonstrates Clinical Utility of SeptiCyte® RAPID to Diagnose Sepsis in Critically Ill Patients with Hospital Acquired Infections
From the PR Newswire post
SeptiCyte® RAPID outperformed traditional inflammatory biomarkers of procalcitonin and C-reactive protein
SEATTLE and BRISBANE, Australia, Sept. 17, 2025 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of a study in the journal Infection. The article, entitled, “Blood transcriptomic for the diagnosis of nosocomial infections in critically ill patients: an observational proof-of-concept study,” may be accessed online.
The prospective, observational, non-interventional study evaluated SeptiCyte® RAPID’s ability to discriminate between sepsis and systemic inflammatory response syndrome (SIRS) in critically ill Intensive Care Unit (ICU) patients diagnosed with nosocomial infections compared to traditional inflammatory biomarkers such as procalcitonin and C-reactive protein. The study enrolled 69 patients with ICU-acquired infection confirmed in 50.7% of patients (n=35). Diagnostic capacity was measured with procalcitonin (PCT) with an AUC of 0.600 (95% CI 0.454– 0.745), C-reactive protein (CRP) with an AUC of 0.703 (95% CI 0.564–0.839), and SeptiCyte RAPID with an AUC of 0.995 (95% CI 0.930–1.003). SeptiCyte RAPID yielded a sensitivity of 91.4%, specificity of 73.5%, and positive and negative predictive values of 78% and 89.3% respectively.